The Biologic Spectrum of Thymic Epithelial Neoplasms: Current Status and Future Prospects

2010 ◽  
Vol 8 (11) ◽  
pp. 1322-1328 ◽  
Author(s):  
Richard T. Cheney

Thymoma is the most common anterior mediastinal tumor in adults and is frequently associated with autoimmune disorders such as myasthenia gravis. Thymomas are a diverse group of epithelial neoplasms with a behavioral spectrum that spans the complete clinical gamut from entirely benign to highly aggressive, lethal thymic carcinomas. The biologic behavior seems to depend primarily on the clinical stage at presentation and histologic subtype. This article discusses thymic organogenesis, Masaoka staging, WHO histologic classification of thymoma and thymic carcinoma, and selected molecular characteristics that highlight this diversity. This discussion will further underscore both the similarities and differences between categories of thymic epithelial neoplasms and offer support for the notion that tumor heterogeneity and/or tumor progression may explain the observed clinical variation in behavior. Recommendations are offered for future investigational approaches to further the understanding of the complexity of these tumors.

2021 ◽  
Vol 8 ◽  
Author(s):  
Sule Yavuz ◽  
Peter E. Lipsky

The vastly diverse nature of systemic lupus erythematosus (SLE) poses great challenges to clinicians and patients, as well as to research and drug development efforts. Precise management of lupus patients would be advanced by the ability to identify specific abnormalities operative in individual patients at the time of encounter with the clinician. Advances in new technologies and bioinformatics have greatly improved the understanding of the pathophysiology of SLE. Recent research has focused on the discovery and classification of sensitive and specific markers that could aid early accurate diagnosis, better monitoring of disease and identification of appropriate therapy choices based on specific dysregulated molecular pathways. Here, we summarize some of the advances and discuss the challenges in moving toward precise patient-centric management modalities in SLE.


2021 ◽  
Author(s):  
Javier Burgos-Salcedo

AbstractThe emergence of a novel SARS-CoV-2 coronavirus at the end of 2019 and its accelerated spread worldwide to become a pandemic has had, from the medical biotechnology point of view, an unprecedented global response, to the point that there are currently 176 vaccine candidates in preclinical stage, 66 in clinical stage, of which 19 are in phase 3, and 5 of these are massively applied worldwide. The purpose of the present work is to elaborate a hierarchical landscape of the current status of phase 3 vaccines, taking into account their attributes of technological platform, safety and efficacy. The methodology used was that of conceptual knowledge representation, resulting in, firstly, an appropriate classification of stage 3 vaccines, The Conceptual Lattice for COVID-19 vaccines, constructed according to how they relate to each other with respect to the set of their attributes. Secondly, the approach used allows proposing rational strategies for the design of heterologous vaccination schemes, which are urgently needed to control the pandemic.


1990 ◽  
Author(s):  
Jesse Orlansky ◽  
Frances Grafton ◽  
Clessen J. Martin ◽  
William Alley ◽  
Bruce Bloxom

2007 ◽  
Vol 2 (6) ◽  
pp. 607-620 ◽  
Author(s):  
James M Wilkins ◽  
John Loughlin ◽  
Sarah JB Snelling

Sign in / Sign up

Export Citation Format

Share Document